Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Integrin alpha V beta 5

Integrin alpha V beta 5

Brief Information

Name:Integrin alpha-V/beta-5
Target Synonym:Receptors, Vitronectin
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

IT5-R52E3-ELISA
 Integrin alpha V beta 5 ELISA

Immobilized Human Vitronectin at 5 μg/mL (100 μL/well) can bind Rat ITGAV&ITGB5 Heterodimer, His Tag&Tag Free (Cat. No. IT5-R52E3) with a linear range of 0.02-0.156 μg/mL (QC tested).

IT5-M82W9-ELISA
 Integrin alpha V beta 5 ELISA

Immobilized Human Fibronectin at 50 μg/mL (100 μL/well) can bind Biotinylated Mouse ITGAV&ITGB5 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT5-M82W9) with a linear range of 0.625-10 μg/mL (Routinely tested).

Synonym Name

Integrin alpha V beta 5,ITGAV&ITGB5

Background

Integrin alpha V beta 5 (ITGAV & ITGB5) is expressed on a wide variety of cell types including keratinocytes, fibroblasts, adhesive monocytes, embryonic stem cells, and select endothelium and epithelium. ITGAV & ITGB5 binds ligands containing an RGD motif, notably vitronectin. Growth factors that increase PKC activity, such as VEGF or TGF alpha, promote ITGAV & ITGB5-mediated angiogenesis while alpha V beta 3, which may be expressed in the same cell, responds to FGF-basic and TNF  alpha. An inhibitor of both down regulates tumor angiogenesis. During lung inflammation, up regulation of ITGAV & ITGB5 on myofibroblasts or infiltrating lymphocytes may contribute to fibrosis by freeing TGF  beta from latency.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Risuteganib ALG-1001; AM011; AM-011(Allegro Ophthalmics) Phase 2 Clinical Allegro Ophthalmics Llc Diabetic macular oedema; Macular Degeneration; Diabetic Retinopathy Details
177Lu-FF-58 177Lu-FF58; 177-Lu-FF-58; 177Lu-FF-58; [177Lu]Lu-FF58 Phase 1 Clinical Advanced Accelerator Applications Sa Esophageal Neoplasms; Stomach Neoplasms; Glioblastoma; Carcinoma, Pancreatic Ductal Details
Internalized-arginylglycylaspartic acid cyclic peptide CEND-1; iRGD; CIND-1; LSTA1; QLC12102 Phase 2 Clinical Drugcendr Inc Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hypopharyngeal Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Colonic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Bile Duct Neoplasms; Oropharyngeal Neoplasms; Carcinoma, Squamous Cell; Gallbladder Neoplasms; Laryngeal Neoplasms; Mouth Neoplasms; Appendiceal Neoplasms; Carcinoma, Pancreatic Ductal Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message